Baclofen
Baclofen Price range: $ 52,00 through $ 498,00
Back to products
Bactrim
Bactrim Price range: $ 41,00 through $ 196,00

Baclosign

Price range: $ 45,00 through $ 803,00

Baclosign is an effective muscle relaxant designed to alleviate severe muscle spasms and cramping. The medication works by targeting the central nervous system to reduce the frequency and severity of involuntary muscle contractions. It is primarily used to manage symptoms associated with multiple sclerosis and various spinal cord injuries or diseases. By relaxing the muscles, Baclosign helps to decrease pain and improve overall physical mobility for patients. This treatment allows individuals to better manage muscle stiffness and regain comfort during their daily activities.

Active substance: Baclofen
SKU: Baclosign Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Baclosign belongs to a class of medications known as central nervous system muscle relaxants and antispasmodics. It contains baclofen as its active pharmaceutical ingredient, which acts primarily at the spinal cord level to reduce excessive skeletal muscle tone and involuntary spasms. This agent is prescribed under strict medical supervision for specific neuromuscular conditions in accordance with United States healthcare standards.

As a prescription-only medication, Baclosign must be dispensed in compliance with applicable federal and state regulations. Patients receiving this therapy require ongoing evaluation by a licensed healthcare professional to establish individualized dosage levels, monitor therapeutic response, and minimize potential adverse effects.

Parameter Details
Active ingredient Baclofen
Therapeutic class Skeletal muscle relaxant / Centrally acting antispasmodic
Dosage form Oral tablet
Route of administration Oral
Primary purpose Management of muscle spasticity
Prescription status Prescription required (Rx only)

Clinical Overview and Mechanism of Action

Main uses

Baclosign is indicated for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. It is also indicated for patients with spinal cord injuries and other traumatic or degenerative spinal cord diseases. By reducing excessive muscular tone, the medication can assist in improving voluntary motor function and facilitating physical therapy or rehabilitation activities. Prescribers may occasionally evaluate off-label applications for specific neurological complaints; however, any off-label use falls outside the standard FDA-approved labeling for this brand. Baclosign is not indicated for muscle spasms caused by acute musculoskeletal injuries or rheumatic disorders.

How the drug works

The precise mechanism of action of Baclosign involves the inhibition of both monosynaptic and polysynaptic reflexes at the spinal cord level. As a structural analog of the primary inhibitory neurotransmitter gamma-aminobutyric acid (GABA), specifically targeting GABA-B receptors, baclofen stimulates these receptors to hyperpolarize ascending nerve terminals. This action restricts the influx of calcium ions into presynaptic terminals, thereby inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate. Consequently, hyperactive muscle contraction signals are reduced. Although the primary therapeutic locus is the spinal cord, general central nervous system depression can also occur, contributing to clinical sedation and muscular relaxation.

How it’s absorbed and eliminated

Following oral administration, Baclosign is rapidly and extensively absorbed from the gastrointestinal tract. Peak plasma concentrations are typically attained within 2 to 3 hours after ingestion, although individual absorption rates can vary based on gastric motility and food co-administration. The drug displays wide distribution throughout body tissues and crosses the blood-brain barrier in modest quantities. Protein binding is relatively low, estimated at approximately 30%. Elimination occurs predominantly through renal pathways, with approximately 70% to 80% of the administered dose excreted unchanged in the urine within 24 hours. The elimination half-life generally ranges between 2.5 and 4 hours in individuals with normal renal function.

Administration, Safety, and Precautions

Dosing schedule

Dosage determination for Baclosign must be individualized to achieve optimal therapeutic benefit while minimizing adverse effects. Therapy typically initiates at a low dose and is titrated incrementally every three days under medical supervision. A standard titration schedule frequently begins at 5 mg administered three times daily, increasing to 10 mg three times daily, and higher if clinically necessary. The maximum recommended total daily oral dosage generally does not exceed 80 mg per day, divided into four equal administrations. Abrupt discontinuation of Baclosign must be strictly avoided, as sudden withdrawal can precipitate severe neurological and autonomic reactions, including hallucinations, confusion, seizures, and rebound spasticity.

What not to combine

Concomitant use of Baclosign with other central nervous system (CNS) depressants significantly increases the risk of severe sedation, respiratory depression, and somnolence. Patients taking sedating antihistamines, opioids, benzodiazepines, barbiturates, or sedating antidepressants must exercise heightened caution. Co-administration with antihypertensive agents may potentiate hypotensive effects, requiring dosage adjustments of blood pressure medications. Additionally, combining Baclosign with tricyclic antidepressants may exacerbate muscle hypotonia and central nervous system depression. Healthcare providers should review all concurrent prescription and over-the-counter medications before initiating therapy.

Adverse reactions

The most frequently reported adverse reaction associated with Baclosign is transient somnolence, which occurs in a substantial proportion of treated patients. Other common central nervous system effects include dizziness, weakness, fatigue, confusion, headache, and insomnia. Gastrointestinal disturbances such as nausea, constipation, dry mouth, and abdominal discomfort are also frequently documented. Cardiovascular reactions may present as hypotension or lightheadedness upon standing. Less common but serious adverse events include neuropsychiatric disturbances, urinary frequency or retention, and respiratory depression. Patients experiencing signs of a severe allergic reaction, such as facial swelling or respiratory distress, require immediate emergency medical evaluation.

Important precautions

Careful medical supervision is required when administering Baclosign to patients with pre-existing renal impairment, as reduced drug clearance can lead to rapid accumulation and clinical toxicity. Patients with a history of psychiatric disorders, epilepsy, cerebrovascular disease, or peptic ulcer disease must be monitored closely. Because Baclosign causes drowsiness and sedation, patients should avoid operating heavy machinery, driving motor vehicles, or participating in hazardous activities until their individual response to the medication is established. Geriatric patients frequently display heightened sensitivity to central nervous system adverse effects, necessitating conservative dose initiation.

Food and alcohol interactions

Baclosign may be taken with food or milk to reduce potential gastrointestinal discomfort or nausea. However, alcohol consumption must be strictly avoided during treatment. Ethanol acts synergistically with baclofen, markedly intensifying central nervous system depression, sedation, motor impairment, and cognitive slowing. Combining alcohol with Baclosign increases the risk of severe hypotension, respiratory compromise, and accidental injuries.

If you skip a dose

If a dose of Baclosign is missed, it should be taken as soon as remembered, provided the time for the next scheduled dose is not imminent. If it is almost time for the subsequent dose, the missed dose should be skipped entirely, and the regular schedule resumed. Double doses should never be taken to compensate for a missed tablet. Taking extra medication increases the risk of acute overdose, severe sedation, and respiratory depression.

Storage and expiration

Baclosign tablets should be stored at controlled room temperature, ideally between 68°F and 77°F (20°C to 25°C), away from excess heat, moisture, and direct light. Storage containers should remain tightly closed when not in use. Keep the medication out of reach of children and pets. Expired or unneeded medication should not be flushed down household drains; utilization of official community drug take-back programs in locations such as Texas or New York is recommended for proper disposal.

Special populations

In pregnant individuals, Baclosign should be used only if the potential therapeutic benefit justifies the potential risk to the fetus, as comprehensive safety data in human pregnancy remains limited. Baclofen crosses the placental barrier, and signs of drug withdrawal have been reported in neonates whose mothers received oral baclofen during pregnancy. The active substance is excreted in human breast milk in small amounts; prescribers must weigh nursing benefits against potential infant risks. Pediatric safety and efficacy in children under twelve years of age have not been established for standard oral formulations.

Common Questions

What should happen if a dose of Baclosign is missed?

Take the missed dose as soon as it is remembered, unless the time for the next scheduled dose is close. Do not take additional tablets to make up for a missed dose, as this elevates the risk of central nervous system toxicity.

Can Baclosign treatment be stopped abruptly?

No. Abrupt cessation of Baclosign can trigger serious withdrawal symptoms, including auditory or visual hallucinations, severe anxiety, high fever, seizures, and rebound spasticity. Discontinuation must be managed gradually under medical direction.

Does Baclosign cause drowsiness or affect motor skills?

Yes, somnolence, dizziness, and impaired muscle coordination are recognized adverse effects. Individuals taking this drug should avoid driving or operating dangerous machinery until they understand how it affects their mental and motor functions.

How does alcohol affect the action of Baclosign?

Alcohol significantly heightens the sedating and CNS-depressant effects of Baclosign. Co-ingestion can cause extreme drowsiness, confusion, reduced blood pressure, and impaired physical balance.

Are there specific risks associated with Baclosign during pregnancy?

Baclofen crosses the placenta and may cause neonatal withdrawal symptoms if taken near delivery. It should only be used during pregnancy when prescribed by a healthcare provider who has evaluated the balance of clinical benefits and potential risks.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

10mg

,

25mg

Package

10 pills

,

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία